Dasatinib Induced Pulmonary Hypertension and Third Space Effusion: A Case Series and Literature Review
Abstract
Dasatinib, a Tyrosine kinase inhibitor, functions by preventing an abnormal protein that instructs cancer cells to proliferate. It is used to treat chronic myeloid leukemia in adults who can no longer benefit from other leukemia medications, including imatinib, or those who cannot tolerate first-line medicines due to their side effects. Pleural effusion and pulmonary hypertension induced by the drug dasatinib are uncommon but serious complications that impact the pulmonary vasculature. Here, we describe a series of patients with chronic myeloid leukemia receiving dasatinib who subsequently experienced pleural effusion and pulmonary hypertension. In 2 of the 3 cases, dasatinib was used as first-line therapy, highlighting the importance of recognizing these adverse effects even when it is used upfront rather than solely after failure of first-generation TKIs. The patient's symptoms significantly improved after stopping dasatinib and starting supportive care. This case series emphasizes the need to raise awareness among clinicians, the importance of early recognition, and the timely initiation of alternative treatment to enhance patient outcomes.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.